CVS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CVS is a good buy right now for a beginner long-term investor with $50,000-$100,000 to allocate. The stock has bullish medium-term momentum, supportive analyst upgrades, positive policy/news catalysts around GLP-1 access, and constructive congress buying. At the current level near $104.51, it is close to resistance but still supported by strong trend structure and favorable long-term fundamentals from recent strategic initiatives. Since the user is impatient and does not want to wait for a perfect entry, I would buy it now.
CVS is in an uptrend. Price is above the 5-day, 20-day, and 200-day moving averages, which is a bullish alignment. MACD histogram is positive at 0.00209, though slightly contracting, suggesting momentum is still positive but not accelerating. RSI_6 at 72.667 indicates strength but is getting extended. Key levels: pivot 102.284, resistance 105.458, then 107.42; support at 99.11 and 97.148. Overall technical setup favors continuation, though near-term upside may be somewhat capped near R1.
["Medicare initiated a temporary obesity-drug coverage program, improving access for millions of seniors.", "Eligible seniors can now access GLP-1 obesity drugs for a $50 monthly copay under Medicare.", "CVS launched a GLP-1 medication program across retail, MinuteClinic, and virtual channels, which can drive pharmacy and digital volume.", "Analysts broadly raised price targets and maintained Buy/Overweight ratings.", "Congress trading data shows 3 purchase transactions and no sales, signaling positive political/influential sentiment."]
["Insiders are selling, and selling activity increased sharply over the last month.", "The stock is trading close to resistance around 105.46, so short-term upside may be limited immediately.", "RSI is elevated, indicating the shares are somewhat extended after recent gains.", "The financial snapshot was unavailable, so the latest quarter numbers could not be directly confirmed from the provided data."]
Latest quarter financials were not fully provided due to a snapshot error, so a detailed quarter-by-quarter review is not available. However, the news and analyst commentary point to improving growth trends: CVS is benefiting from GLP-1 access expansion, better managed care utilization trends, margin recovery in government business, and stronger commercial performance. The latest referenced quarter in analyst notes appears to be Q1 2026, with commentary that Q1 medical cost trends were favorable and guidance retained an upward bias.
Analyst sentiment is clearly positive and has been improving. Over the last month, multiple firms raised price targets: BofA to $110, Morgan Stanley to $111 and earlier to $106, Truist to $108, Barclays to $106, Mizuho to $110, JPMorgan to $111, TD Cowen to $110, Wells Fargo to $103, and Bernstein to $106. Ratings remain mostly Buy/Overweight/Outperform. Wall Street pros view CVS as having attractive Medicare Advantage turnaround potential, steadier pharmacy/PBM earnings, and reduced PBM uncertainty. The main con is that some of the optimism is already reflected in the recent multiple expansion.
